tiprankstipranks
Advertisement
Advertisement

BLCO Stock Latest News

Bausch + Lomb Shareholders Back Board and Executive Pay
Company AnnouncementsBausch + Lomb Shareholders Back Board and Executive Pay
16h ago
8K
BLCO
Bausch + Lomb announces U.S. launch of PreserVision AREDS3
PremiumThe Fly
Bausch + Lomb announces U.S. launch of PreserVision AREDS3
2d ago
BLCO
Bausch + Lomb launches Bi-Blade+ dual-port vitrectomy cutter in Europe
PremiumThe Fly
Bausch + Lomb launches Bi-Blade+ dual-port vitrectomy cutter in Europe
14d ago
BLCO
Bausch + Lomb Lifts Outlook After Margin-Heavy Quarter
PremiumCompany Announcements
Bausch + Lomb Lifts Outlook After Margin-Heavy Quarter
21d ago
BLCO
Bausch + Lomb price target lowered to $16 from $17 at Evercore ISI
PremiumThe Fly
Bausch + Lomb price target lowered to $16 from $17 at Evercore ISI
21d ago
BLCO
Bausch + Lomb price target lowered to $16 from $18 at Deutsche Bank
PremiumThe FlyBausch + Lomb price target lowered to $16 from $18 at Deutsche Bank
21d ago
BLCO
Bausch + Lomb price target lowered to C$19 from C$21 at Citi
Premium
The Fly
Bausch + Lomb price target lowered to C$19 from C$21 at Citi
21d ago
BLCO
Bausch + Lomb: Solid Q1 Beat and Pharma Momentum Offset by Spin-Off Uncertainty, Supporting Hold Rating
Premium
Ratings
Bausch + Lomb: Solid Q1 Beat and Pharma Momentum Offset by Spin-Off Uncertainty, Supporting Hold Rating
22d ago
BLCO
Bausch + Lomb reports Q1 adjusted EPS 5c, consensus 5c
PremiumThe Fly
Bausch + Lomb reports Q1 adjusted EPS 5c, consensus 5c
22d ago
BLCO
Bausch + Lomb raises FY26 revenue view to $5.420B-$5.530B from $5.375B-$5.475B
PremiumThe Fly
Bausch + Lomb raises FY26 revenue view to $5.420B-$5.530B from $5.375B-$5.475B
22d ago
BLCO
Bausch + Lomb announces narrative review on certain B vitamins
PremiumThe Fly
Bausch + Lomb announces narrative review on certain B vitamins
28d ago
BLCO
Bausch + Lomb reports nearly 725k lbs. of eye care materials recycled
PremiumThe Fly
Bausch + Lomb reports nearly 725k lbs. of eye care materials recycled
1M ago
BLCO
Bausch + Lomb Wins FDA Clearance for Next-Generation Vitrectomy Cutter and Fluidics Upgrade
PremiumCompany AnnouncementsBausch + Lomb Wins FDA Clearance for Next-Generation Vitrectomy Cutter and Fluidics Upgrade
1M ago
BLCO
Bausch + Lomb receives FDA 510k clearance for Bi-Blade+
Premium
The Fly
Bausch + Lomb receives FDA 510k clearance for Bi-Blade+
1M ago
BLCO
Bausch + Lomb Rolls Out enVista Envy Premium Intraocular Lens Across Europe
Premium
Company Announcements
Bausch + Lomb Rolls Out enVista Envy Premium Intraocular Lens Across Europe
1M ago
BLCO
Bausch + Lomb announces European availability of enVista Envy lenses
PremiumThe Fly
Bausch + Lomb announces European availability of enVista Envy lenses
1M ago
BLCO
Bausch + Lomb to Unveil Broad New Ophthalmic Data at ASCRS Meeting
PremiumCompany Announcements
Bausch + Lomb to Unveil Broad New Ophthalmic Data at ASCRS Meeting
2M ago
BLCO
Bausch + Lomb price target lowered to $17 from $17.50 at Evercore ISI
PremiumThe Fly
Bausch + Lomb price target lowered to $17 from $17.50 at Evercore ISI
2M ago
BLCO
Bausch + Lomb Sets Date for First-Quarter 2026 Results and Investor Call
PremiumCompany Announcements
Bausch + Lomb Sets Date for First-Quarter 2026 Results and Investor Call
2M ago
BLCO
Bausch + Lomb’s ELIOS Glaucoma System Hits Key Efficacy Marks in 24‑Month U.S. Trial
PremiumCompany AnnouncementsBausch + Lomb’s ELIOS Glaucoma System Hits Key Efficacy Marks in 24‑Month U.S. Trial
2M ago
BLCO
Bausch + Lomb announces 24-month U.S. data on ELIOS system in Glaucoma
Premium
The Fly
Bausch + Lomb announces 24-month U.S. data on ELIOS system in Glaucoma
2M ago
BLCO
Bausch + Lomb Launches R&D Webinar Series Spotlighting Glaucoma Pipeline
Premium
Company Announcements
Bausch + Lomb Launches R&D Webinar Series Spotlighting Glaucoma Pipeline
2M ago
BLCO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >